RxDoctor Payments Data

Glenn Vanotteren, MD

Critical Care Medicine · Grand Rapids, MINPI 1700826880

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Galvanize Therapeutics, Inc at 24.4% of the total. 2025 is the largest year on record at $541, more than ten times the $26 reported in 2019.

$1,291in general payments, 2019–2025

Across 26 payments — averaging $49.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galvanize Therapeutics, Inc$315
  • Inari Medical, Inc.$156
  • Medical Device Business Services, Inc.$150
  • Inspire Medical Systems, Inc.$136
  • Johnson & Johnson$107
  • Intuitive Surgical$83
  • plus $343 from 13 others

What the payments were for

  • Food & beverage$1,291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,291 in reported general payments places this provider in the 75th percentile of 177 critical care medicine providers in Michigan.

See all critical care medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$26,252
Medicare patients
102
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$27,124
Spiriva RespimatTiotropium Bromide33$16,468
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$12,590
DuleraMometasone/Formoterol12$12,138
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$7,810
Breo ElliptaFluticasone/Vilanterol11$4,214
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,632
Albuterol Sulfate HfaAlbuterol Sulfate51$2,502
Montelukast Sodium24$406
Azithromycin16$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat$28$16,46833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 critical care medicine providers in Michigan.

Other critical care medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →